LOGIN  |  REGISTER
Amneal Pharmaceuticals

Glaukos (NYSE: GKOS) Stock Quote

Last Trade: US$93.34 0.65 0.70
Volume: 114,335
5-Day Change: 6.93%
YTD Change: 17.42%
Market Cap: US$4.620B

Latest News From Glaukos

ALISO VIEJO, Calif. / Feb 21, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023. Key highlights include: Record net sales of $82.4 million in Q4 2023 increased 16%... Read More
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Jan 31, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2023 financial results after the market close on Wednesday, February 21, 2024. The... Read More
ALISO VIEJO, Calif. / Jan 09, 2024 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023. Preliminary and unaudited total net sales for the fourth quarter and... Read More
ALISO VIEJO, Calif. / Dec 20, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 5:15 p.m. PT in San Francisco,... Read More
Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity iDose TR was designed to usher in a new era of interventional glaucoma by enabling a proactive approach with a safe, effective, and durable therapy for patients in need FDA approval based on robust Phase 3 clinical program consisting of two pivotal studies that randomized 1,150 subjects across 89 clinical sites Glaukos to host... Read More
ALISO VIEJO, Calif. / Nov 07, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Stifel Healthcare Conference on Tuesday, November 14, 2023, at 10:55 a.m. ET in New York City. A live and... Read More
ALISO VIEJO, Calif. / Nov 01, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the third quarter ended September 30, 2023. Key highlights include: Net sales of $78.0 million in Q3 2023 increased 10% year-over-year on a... Read More
ALISO VIEJO, Calif. / Oct 31, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 3-6, 2023... Read More
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Oct 11, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2023 financial results after the market close on Wednesday, November 1, 2023. The company’s... Read More
ALISO VIEJO, Calif. / Aug 23, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 6, 2023, at 12:45 p.m. ET in Boston, MA. A live and... Read More
ALISO VIEJO, Calif. / Aug 02, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2023. Key highlights include: Net sales of $80.4 million in Q2 2023 increased 11% year-over-year. Glaucoma net... Read More
Advancing Next-Generation Wearable Patient Engagement and Diagnostic Technology Designed to Enable More Efficient Detection of Eye Diseases ALISO VIEJO, Calif. / Jul 17, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a... Read More
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Jul 12, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2023 financial results after the market close on Wednesday, August 2, 2023. The company’s... Read More
Enrollment Completion Achieved in Less Than Six Months from Trial Commencement, Ahead of Original Timing Expectations Phase 3 Confirmatory Trial Results Together with Already-Completed First Phase 3 Trial Expected to Support Glaukos’ Targeted NDA Submission for Epioxa by the End of 2024 ALISO VIEJO, Calif. / Jun 05, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical... Read More
ALISO VIEJO, Calif. / May 24, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the William Blair 43 rd Annual Growth Stock Conference on Wednesday, June 7, 2023, at 10:40 a.m. CT in Chicago, IL.... Read More
PDUFA Date Set for December 22, 2023 ALISO VIEJO, Calif. / May 05, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted... Read More
ALISO VIEJO, Calif. / May 03, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2023. Key highlights include: Net sales of $73.9 million in Q1 2023 increased 9% year-over-year on a reported... Read More
ALISO VIEJO, Calif. / May 01, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held... Read More
ALISO VIEJO, Calif. / Apr 19, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has published its 2022 Sustainability Report. The report highlights the company’s continued commitment and progress on environmental, social and governance... Read More
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Apr 12, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first quarter 2023 financial results after the market close on Wednesday, May 3, 2023. The company’s management... Read More
ALISO VIEJO, Calif. / Feb 27, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for iDose ® TR . iDose TR is a micro-invasive intraocular implant... Read More
ALISO VIEJO, Calif. / Feb 22, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2022. Key highlights include: Net sales of $71.2 million in Q4 2022. Glaucoma net sales of... Read More
ALISO VIEJO, Calif. / Feb 15, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Citi Healthcare Conference on Wednesday, March 1, 2023, at 1:15 p.m. ET in New York City. A live and archived... Read More
Conference Call and Webcast Scheduled for 1:30 p.m. PT ALISO VIEJO, Calif. / Feb 01, 2023 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2022 financial results after the market close on Wednesday, February 22, 2023. The... Read More
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive results for a prospective, multi-center clinical trial designed to evaluate the safety of the surgical exchange procedure for iDose ® TR (travoprost intraocular implant) in subjects who had previously been... Read More
Commencement of Subject Enrollment in Epioxa™ Phase 3 Confirmatory Trial Promising Phase 2a Results for GLK-301 (iLution – Dry Eye Disease) Support Planned Phase 2b Study to Commence in 2023 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced positive clinical updates for... Read More
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the 41 st Annual J.P Morgan Healthcare Conference on Tuesday, January 10, 2023, at 5:15 p.m. PT in San Francisco, CA. A live and archived webcast for this event will be... Read More
Chimerix

COPYRIGHT ©2023 HEALTH STOCKS HUB